



Presented by  
Management Forum

# Deep Dive into the IVDR Annex XIII

5 November 2024

+ 5 March 2025, 10 July 2025, 5 November 2025

Explore IVDR Annex XIII in-depth, covering Performance Evaluation, Performance Studies, and Post-market Performance. Learn what information is required, where to put it, and when, with a detailed review of nine essential documents.



**Format:**  
Live online



**CPD:**  
6 hours for your records



Certificate of  
completion

# Course overview

## Understand where, when and how performance evaluation should be undertaken during the life cycle of an IVD device under the IVDR (2017/746).

The EU *In Vitro* Diagnostic Medical Device Regulation (IVDR) 2017/746, came into force in May 2017, with an initial transition period of five years, and an intention to strengthen the current approval system for *in vitro* diagnostics in Europe through an evidenced based Notified Body review system. A key area of change is the minimisation of self-certification, and the introduction of mandatory documentation for the planning and reporting of the manufacturer's clinical evidence to demonstrate the safety and effectiveness of the IVD device under evaluation.

IVDeology and Management Forum have developed a highly interactive training programme to provide a deep-dive into the nine documents mandated in Annex XIII - Performance Evaluation, Performance Studies and Post-market Performance.

We shall answer what information is required, where to put it and when. The primary documents we will review are as follows:

- Performance Evaluation Plan
- Scientific Validity Report
- Analytical Performance Report
- Clinical Performance Study Plan
- Clinical Performance Study Report
- Clinical Performance Report
- Performance Evaluation Report
- Post-Market Performance Follow-up Plan
- Post-Market Performance Follow-up Report

### Special offer:

Expand your understanding of IVDR requirements by also attending our '[Introduction to the New Performance Evaluation Requirements Mandated Under the IVDR \(2017/746\)](#)' course. This training provides a comprehensive overview of performance evaluation throughout the life cycle of an IVD device, essential for ensuring regulatory compliance.

**Sign up for both and receive the second course at 50% off.** Please [contact us](#) at [info@ipi.academy](mailto:info@ipi.academy) to take advantage of this offer.

## Benefits of attending

- **Gain** a comprehensive overview of documents mandated within Annex XIII of the IVDR
- **Enhance** your understanding of key concepts used within IVDR performance evaluation
- **Understand** the purpose and scope of each document and their interrelationships
- **Learn** how to draft documents to assist Notified Body reviews

## Who should attend?

Professionals involved in the research, development, or manufacturing of *in vitro* diagnostic medical devices, including:

- Senior management
- Regulatory affairs personnel
- Quality assurance professionals
- Product development personnel
- Project managers
- R&D personnel
- Clinical performance study personnel
- Pharmaceutical/CRO clinical trial managers

# Programme

## **IVDR Introduction**

- Global overview of IVD Regulation
- Performance evaluation within IVDR

## **Performance evaluation plan (PEP)**

- What is the purpose of the PEP
- Value to the manufacturer
- When should it be written
- What should it contain

## **Scientific validity report (SVR)**

- What is the purpose of the SVR
- Value to the manufacturer
- When should it be written
- What should it contain

## **Clinical performance study plan (CPSP)**

- IVDR versus ISO 20916
- The types of clinical performance study
- Clinical performance studies that require application to competent authorities
- What is required in a CPSP

## **Performance evaluation report (PER)**

- What is the purpose of the Analytical performance report (APR), Clinical performance report (CPR) and PER
- Value to the manufacturer
- When should they be written
- What should they contain

## **Post-market performance follow-up (PMPF)**

- What is it and how should it be used
- What would a PMPF plan contain
- Notified body expectations

# Presenter



## Jane Leadsham

Jane Leadsham is a IVD Medical Device professional with 10 years experience gained working in *in vitro* diagnostic Medical device development firstly for Novartis Pharmaceuticals, and currently as a consultant regulatory medical writer. Jane specializes in supporting IVD manufacturers to meet the performance evaluation requirements of (EU) IVD Regulation 2017/746.

Jane has held several senior R&D scientist roles for both an *in vitro* diagnostic manufacturer and a biotech company and completed a five-year post-doctoral research project at the University of Kent. This cross-sector industry/academia experience has provided Jane with a thorough but diverse knowledge of research, development and product commercialization.

As a consultant medical writer to the IVD industry, under the (EU) IVD Regulations 2017/746, Jane has worked on end-to-end projects, including with Notified Bodies, and successfully completed CE certification of a Class C IVD device. Jane has completed performance evaluation documents for:

- three CDx devices including preparation of documents required for interventional performance evaluation studies,
- legacy devices transitioning from IVDD to IVDR, Classes A to D, and
- new devices in Classes A to C,
- complete sample to result fully automated systems, and
- near-patient testing/point of care device

Jane has also provided training programs on the performance evaluation requirements of the (EU) IVD Regulation 2017/746 to five device manufacturers. One manufacturer, with a complex, near-patient testing, Class D device, used Jane to provide template documents and regular on-going training and support for staff to complete the performance evaluation documents themselves. Further, Jane has acted as a third-party reviewer for performance evaluation documents written by external contractors, including AI.

As a Principal Scientist, and member of a near-patient testing device development team, with Novartis Pharmaceuticals, Jane led a group of scientists in conjunction with a CRO to design, develop and manufacture a key component of a cardiac marker immunoassay within the target timeline. Jane was part of the team that planned and executed a prospective clinical trial to assess the performance of the near-patient device .

# Course dates

5 November 2024

Live online

09:30-16:15 **UK (London)** (UTC+00)

Course code 15218

GBP ~~549~~ 649

EUR ~~789~~ 929

USD ~~893~~ 1,049

Until 01 Oct

5 March 2025

Live online

09:30-16:15 **UK (London)** (UTC+00)

Course code 15219

GBP ~~549~~ 649

EUR ~~789~~ 929

USD ~~893~~ 1,049

Until 29 Jan

10 July 2025

Live online

09:30-16:15 **UK (London)** (UTC+01)

Course code 15220

GBP ~~549~~ 649

EUR ~~789~~ 929

USD ~~893~~ 1,049

Until 05 Jun

5 November 2025

Live online

09:30-16:15 **UK (London)** (UTC+00)

Course code 15228

GBP ~~549~~ 649

EUR ~~789~~ 929

USD ~~893~~ 1,049

Until 01 Oct

## How to book



Online:

[ipi.academy/2913](https://ipi.academy/2913)

Alternatively contact us to book, or if you have any queries:



Email:

[info@ipi.academy](mailto:info@ipi.academy)



Phone:

[+44 \(0\)20 7749 4749](tel:+44(0)2077494749)

## Discounts

- Booking more than one delegate on any one date qualifies for a **15% discount** on the second and subsequent places.
- Most events qualify for an **early booking discount** prior to 6 weeks before the course date. Be sure to check on our website, where the latest discounts will be shown.

## Further information

### Fee

The fee includes all meals and refreshments for the duration of the course (for venue-based courses) and a complete set of course materials (provided electronically). If you have any particular requirements, please advise customer services when booking.

### Please note

IPI Academy (and our training partners) reserve the right to change the content and timing of the programme, the speakers, the date and venue due to reasons beyond their control. In the unlikely event that the course is cancelled, we will refund the registration fee and disclaim any further liability.

### Terms and conditions

The rest of our terms, the event cancellation policy and the terms and conditions are on our website, please visit [ipi.academy/content/terms-and-conditions](https://ipi.academy/content/terms-and-conditions)

## Run this programme in-house for your whole team

Coming to IPI Academy for your in-house training provides an all-inclusive service which gives you access to a wide variety of content, learning platforms and delivery mechanisms as well as your own personal training adviser who will work with you from the initial enquiry through to feedback and follow-up after the programme.

With over 600 trainers, all practitioners and experts across a huge range of fields, we can provide the training you need, where you need it, when you need it, and at a price which suits your budget. Our approach to tailored learning and development consists of designing and delivering the appropriate solution for each client.

For your FREE consultation and to find out more about how we can work with you to solve your training needs, please contact our training advisers:



**ALEKSANDRA BEER**

**Tel:** +44 (0)20 7749 4749

**Email:** [inhouse@ipi.academy](mailto:inhouse@ipi.academy)



**YESIM NURKO**

**Tel:** +44 (0)20 7749 4749

**Email:** [inhouse@ipi.academy](mailto:inhouse@ipi.academy)



**IPI**  
Academy

IPI Academy is a training initiative of Falconbury and Management Forum; leading providers of industry training for over 30 years, based in the UK.

10-12 Rivington Street  
London EC2A 3DU

[ipi.academy](http://ipi.academy)

**Tel:** +44 (0)20 7749 4749

**Email:** [info@ipi.academy](mailto:info@ipi.academy)